Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27033007 | 0.98 | KMT2A (0.47) | KMT2AHTR6PKMALDH1A1CA2 | |
| SCHEMBL5848016 | 0.78 | GAA (0.54) | KMT2AALDH1A1CA2CA12CA9 | |
| SCHEMBL9709553 | 0.77 | ALDH1A1 (0.46) | KMT2AHTR6PKMALDH1A1CA2 | |
| SCHEMBL875132 | 0.76 | KMT2A (0.46) | KMT2AHTR6PKMALDH1A1CA2 | |
| SCHEMBL17023196 | 0.73 | CA2 (0.48) | KMT2AHTR6ALDH1A1CA2CA12 | |
| SCHEMBL2588031 | 0.73 | SMN1; SMN2 (0.48) | KMT2AHTR6PKMALDH1A1CA2 | |
| SCHEMBL8537935 | 0.73 | ALDH1A1 (0.48) | KMT2AHTR6PKMALDH1A1CA2 | |
| SCHEMBL8522574 | 0.72 | HTR6 (0.50) | HTR6ALDH1A1CA2CA12CA9 | |
| SCHEMBL8547987 | 0.72 | ALDH1A1 (0.52) | HTR6ALDH1A1CA2CA12CA9 | |
| SCHEMBL1465801 | 0.72 | HTR6 (0.50) | HTR6ALDH1A1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 432 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12537221-B2 | Electrolyte for secondary battery and secondary battery including the same | DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-01-27 | — | — | US | claimed |
| WO-2024110477-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-30 | — | — | WO | claimed |
| WO-2024042448-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB | GRANULES INDIA LIMITED (IN) | 2024-02-29 | — | — | WO | claimed |
| WO-2024028999-A1 | METHOD FOR PRODUCING N-[4-METHYLAMINOBENZOYL]-L-GLUTAMIC ACID DIETHYL ESTER | ILS株式会社 | 2024-02-08 | — | — | WO | claimed |
| US-20220407116-A1 | ELECTROLYTE FOR SECONDARY BATTERY AND SECONDARY BATTERY INCLUDING THE SAME | DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-12-22 | — | — | US | claimed |
| US-10081633-B2 | Adenylyl cyclase inhibitors, pharmaceutical compositions and method of use thereof | VASADE BIOSCIENCES, INC. | 2018-09-25 | — | — | US | claimed |
| WO-2017222946-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | VASADE BIOSCIENCES (US) | 2017-12-28 | — | — | WO | claimed |
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | VASADE BIOSCIENCES, INC. | 2017-12-21 | — | — | US | claimed |
| US-8835685-B2 | Process for the preparation of contrast agents | BRACCO IMAGING S.P.A. (IT) | 2014-09-16 | — | — | US | claimed |
| EP-2593423-B1 | PROCESS FOR THE PREPARATION OF CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2014-09-03 | — | — | EP | claimed |
| US-6660764-B2 | Telomerase inhibitors such as trans-3-(benzothien-6-yl)-but-2-enoic acid-N-(2-carboxy-phenyl)-amide; use as antitumor agent | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-12-09 | — | — | US | claimed |
| EP-1066276-A1 | PROCESS FOR THE SYNTHESIS OF HIV PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-01-10 | — | — | EP | claimed |
| WO-1999048885-A1 | PROCESS FOR THE SYNTHESIS OF HIV PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-09-30 | — | — | WO | claimed |
| US-5889131-A | HEAT RESISTANCE, TRANSPARENCY AND MELT PROCESSABILITY; THIN FILMS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 1999-03-30 | — | — | US | claimed |
| US-5508273-A | ARALKYLPHOSPHONATES FOR OSTEOPOROSIS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-04-16 | — | — | US | claimed |
| EP-0180813-B1 | CHROMOGENIC 4,4-DIARYLDIHYDROCHINAZOLONES, THEIR PREPARATION AND USE | BAYER AG (DE) | 1988-06-01 | — | — | EP | claimed |
| EP-0180813-A1 | Chromogenic 4,4-diaryldihydrochinazolones, their preparation and use | BAYER AG (DE) | 1986-05-14 | — | — | EP | claimed |
| US-4347375-A | Process for preparing amino acids and esters | MERCK & CO., INC. (US) | 1982-08-31 | — | — | US | claimed |
| US-4117145-A | DIURETIC, HYPOTENSIVE, ANTITHROMBOTIC AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1978-09-26 | — | — | US | claimed |
| US-4117143-A | USED AS ANTITHROMBOTIC AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1978-09-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12537221-B2 | Electrolyte for secondary battery and secondary battery including the same | NCS1, KCNN2, SLC9A1 | KMT2A 810/4885HTR6 3976/4885PKM 2798/4885 |
| US-10081633-B2 | Adenylyl cyclase inhibitors, pharmaceutical compositions and method of use thereof | ADCY1, ADCY2, ADCY5 | KMT2A 4301/4885HTR6 1762/4885PKM 2755/4885 |
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | ADCY1, ADCY2, ADCY5 | KMT2A 4301/4885HTR6 1762/4885PKM 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.